 AUSTIN, Texas, March 18, 2021 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ:AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its fourth quarter and full year 2020 financial results, and provided recent corporate and program highlights. 2020 was a challenging year advancing our clinical trials and at the same time prioritizing the health and well-being of the rare disease patients we serve, who often have additional difficulties and vulnerabilities, said Anthony Quinn, M.B Ch.B, Ph.D. 